DELCATH SYSTEMS –

Stamford, Conn.

Went public 10/20/00 at $6 per share

Filing Range:1.2 million shares @ $6

Shares Outstanding:3.9 million shares

Underwriters: Whale Securities Co.

Company Counsel: Morse, Zelnick, Rose & Lander LLP

Manager Counsel: Blank, Rome, Comisky & McCauley

Auditor: KPMG LLP

The Company:

Develops treatments for liver cancer. Delcath has developed a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

Venture Backers

Venkol Ventures

Johnson & Johnson Development Corp.

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 02/22/1988 1 Early Stage 500.0

2 01/23/1991 1 Expansion 1063.0

3 12/01/1992 1 Expansion 1050.0

4 12/01/1997 2 Expansion 610.0

5 06/01/1999 1 Expansion 776.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $0.0

Net Income: -0.6